Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $3.04, up 2.87% on the session, giving a market capitalisation of $192.9M. On trailing twelve-month figures it carries a trailing P/E of -2.16, a net margin of -803.8%. Its beta of 1.32 implies it has historically moved more than the broad market.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Pyxis Oncology, Inc. is most often compared with the following Healthcare names: